ES2193142T3 - Uso de benzotiofenos para el tratamiento de hipercolesterolemia. - Google Patents

Uso de benzotiofenos para el tratamiento de hipercolesterolemia.

Info

Publication number
ES2193142T3
ES2193142T3 ES93310438T ES93310438T ES2193142T3 ES 2193142 T3 ES2193142 T3 ES 2193142T3 ES 93310438 T ES93310438 T ES 93310438T ES 93310438 T ES93310438 T ES 93310438T ES 2193142 T3 ES2193142 T3 ES 2193142T3
Authority
ES
Spain
Prior art keywords
substituted
aryloxicarbonyloxi
metoxi
hydroxyl
benzotiophenes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93310438T
Other languages
English (en)
Inventor
Larry John Black
Henry Uhlman Bryant
George Joseph Cullinan
Raymond Francis Kauffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2193142T3 publication Critical patent/ES2193142T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Bipolar Transistors (AREA)
  • Semiconductor Lasers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EMPLEO DE UN COMPUESTO DE FORMULA (I): EN DONDE N ES 0, 1 O 2; R ES HIDROXILO METOXI, ALCANOILOXI C1 OXI C3 SUBSTITUIDO O NO SUBSTITUIDO, O ARILOXICARBONILOXI SUBSTITUIDO O NO SUBSTITUIDO; R1 ES HIDROGENO, HIDROXILO, CLORO, BROMO, METOXI, ALCANOILOXI C1 XI C1 ITUIDO, O ARILOXICARBONILOXI SUBSTITUIDO O NO SUBSTITUIDO; R2 ES UN ANILLO HETEROCICLICO SELECCIONADO DEL GRUPO QUE CONSISTE EN PIRROLIDINO, PIPERIDINO, O HEXAMETILENOIMINO; O UNA SAL O SOLVATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO EN LA PREPARACION DE UN MEDICAMENTO UTIL PARA REDUCIR LOS NIVELES DE COLESTEROL EN SUERO EN LOS ANIMALES.
ES93310438T 1992-12-22 1993-12-22 Uso de benzotiofenos para el tratamiento de hipercolesterolemia. Expired - Lifetime ES2193142T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99522292A 1992-12-22 1992-12-22

Publications (1)

Publication Number Publication Date
ES2193142T3 true ES2193142T3 (es) 2003-11-01

Family

ID=25541537

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93310438T Expired - Lifetime ES2193142T3 (es) 1992-12-22 1993-12-22 Uso de benzotiofenos para el tratamiento de hipercolesterolemia.

Country Status (28)

Country Link
US (1) US5464845A (es)
EP (2) EP1238667A3 (es)
JP (1) JP3197129B2 (es)
KR (1) KR100278946B1 (es)
CN (1) CN1043608C (es)
AT (1) ATE233559T1 (es)
AU (1) AU669235B2 (es)
BG (1) BG61524B1 (es)
BR (1) BR9305182A (es)
CA (1) CA2112017C (es)
CZ (1) CZ283863B6 (es)
DE (1) DE69332735T2 (es)
DK (1) DK0605193T3 (es)
ES (1) ES2193142T3 (es)
HU (1) HU223342B1 (es)
IL (1) IL108042A (es)
MY (1) MY109345A (es)
NO (1) NO304924B1 (es)
NZ (1) NZ250486A (es)
PH (1) PH30430A (es)
PL (1) PL177349B1 (es)
RO (1) RO113806B1 (es)
RU (1) RU2123335C1 (es)
SG (1) SG52696A1 (es)
SK (1) SK279271B6 (es)
TW (1) TW383306B (es)
YU (1) YU48918B (es)
ZA (1) ZA939427B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
CZ306394A3 (en) * 1993-12-14 1995-08-16 Lilly Co Eli Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
DE69428882T2 (de) * 1993-12-21 2002-04-25 Eli Lilly And Co., Indianapolis Verwendung von Raloxifen und dessen Analogen zur Herstellung eines Medikaments zur Behandlung von Atherosklerose und ischämischer Herzerkrankungen
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
EP0716854A3 (en) * 1994-10-20 1996-08-28 Lilly Co Eli Compositions for inhibiting neuropeptide Y
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
CA2215902A1 (en) * 1995-04-21 1996-10-24 Charles David Jones Benzothiophenes with novel basic side chains
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
US6008377A (en) * 1996-03-19 1999-12-28 Eli Lilly And Company Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxy-benzo[B]thiophenes
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
CA2206752A1 (en) * 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
BR9809439A (pt) * 1997-04-30 2000-06-13 Lilly Co Eli Processos para preparação de benzotiofenos
AU7261498A (en) * 1997-04-30 1998-11-24 Eli Lilly And Company Intermediates and processes for preparing benzo{b}thiophenes
CA2287918A1 (en) * 1997-04-30 1998-11-05 John Mcneill Mcgill Iii A regioselective alkylation process for preparing substituted benzo¬b|thiophenes
CA2231013A1 (en) * 1997-04-30 1998-10-30 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
WO1998048787A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company INTERMEDIATES AND A PROCESS FOR PREPARING BENZO[b]THIOPHENES
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
RU2233162C2 (ru) * 1999-02-06 2004-07-27 Астразенека Аб Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s)-3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4
PL356662A1 (en) 1999-12-22 2004-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
ES2274854T3 (es) * 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
SG162615A1 (en) * 2002-06-13 2010-07-29 Wyeth Corp Bazedoxifene treatment regimens
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
WO2005060946A1 (en) * 2003-12-17 2005-07-07 Pfizer Products Inc. Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass
WO2009018165A2 (en) 2007-07-27 2009-02-05 Container Stuffers, Llc Cargo loader
CN101669557B (zh) * 2009-08-20 2012-07-25 杭州六易科技有限公司 一种清热解毒凉茶的制作方法
WO2016021706A1 (ja) * 2014-08-08 2016-02-11 カズマパートナーズ株式会社 縮合複素環化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
ES541841A0 (es) * 1983-06-24 1985-12-01 Yamanouchi Pharma Co Ltd Un procedimiento para la preparacion de un compuesto fenoxi
EP0166025A3 (en) * 1984-06-27 1986-08-20 American Cyanamid Company Non-antibiotic animal feed additive compositions
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
AT391316B (de) * 1988-09-15 1990-09-25 Ebewe Arzneimittel Neue thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene

Also Published As

Publication number Publication date
IL108042A (en) 1998-01-04
DK0605193T3 (da) 2003-03-31
JP3197129B2 (ja) 2001-08-13
NO304924B1 (no) 1999-03-08
EP0605193A1 (en) 1994-07-06
HU223342B1 (hu) 2004-06-28
HUT69686A (en) 1995-09-28
JPH06234632A (ja) 1994-08-23
KR940013501A (ko) 1994-07-15
CA2112017A1 (en) 1994-06-23
NO934740L (no) 1994-06-23
SK279271B6 (sk) 1998-08-05
AU5257893A (en) 1994-07-07
DE69332735D1 (de) 2003-04-10
DE69332735T2 (de) 2003-10-23
CZ279093A3 (en) 1994-07-13
AU669235B2 (en) 1996-05-30
PL177349B1 (pl) 1999-10-29
RO113806B1 (ro) 1998-11-30
CA2112017C (en) 2005-06-14
US5464845A (en) 1995-11-07
SG52696A1 (en) 1998-09-28
CN1094042A (zh) 1994-10-26
TW383306B (en) 2000-03-01
NO934740D0 (no) 1993-12-21
IL108042A0 (en) 1994-04-12
PL301579A1 (en) 1994-06-27
RU2123335C1 (ru) 1998-12-20
CN1043608C (zh) 1999-06-16
YU79893A (sh) 1997-05-28
BG61524B1 (bg) 1997-11-28
PH30430A (en) 1997-05-09
EP1238667A2 (en) 2002-09-11
HU9303676D0 (en) 1994-04-28
YU48918B (sh) 2002-11-15
SK142193A3 (en) 1995-01-12
ATE233559T1 (de) 2003-03-15
KR100278946B1 (ko) 2001-01-15
ZA939427B (en) 1995-06-15
BR9305182A (pt) 1994-08-16
EP1238667A3 (en) 2003-12-10
NZ250486A (en) 1997-06-24
EP0605193B1 (en) 2003-03-05
MY109345A (en) 1997-01-31
BG98317A (en) 1995-02-28
CZ283863B6 (cs) 1998-06-17

Similar Documents

Publication Publication Date Title
ES2051700T3 (es) Un proceso para la preparacion de un compuesto beta-lactama.
AR015987A1 (es) DERIVADOS DE PLEUROMUTILINA, COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, Y, SU USO PARA LA ELABORACIoN DE UN MEDICAMENTO.
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ATE161731T1 (de) Anwendung von nor- und homo-gallensäurederivaten als absorptienförderer für arzneimittel
SE9002206D0 (sv) New compounds
DE69310602D1 (de) 3',5'-Ditertbutyl-4'-Hydroxyflavone, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzung mit Antioxidations- und Antivasokonstriktionsaktivität
ATE48602T1 (de) Beta-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ES2071668T3 (es) Benzopirano y compuestos relacionados.
DE59005254D1 (de) 24-Homo-Vitamin-D-Derivate, Verfahren zu ihrer Herstellung; diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung als Arzneimittel.
SE8600632D0 (sv) Novel pharmaceutical composition
ES2090083T3 (es) Derivados de cefalosporina, procedimiento para su preparacion y composicion antimicrobiana que contiene estos derivados.
ATE41772T1 (de) Polymethoxybenzyl-piperazin-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen.
AU549890B2 (en) Para-substituted-3-phenoxy-1-alkoxycarbenyl-alkylamino- propanol-2 compounds
ES2093246T3 (es) Compuestos de benzazepina terapeuticos.
PT84934A (fr) Nouveaux derives de synergistines leur preparation et les compositions pharmaceutiques qui les contiennent
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.
ATE5961T1 (de) N-acylpeptid-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
IL97855A0 (en) Bromide containing pharmaceutical compositions for treatment of psoriasis
EP0302757A3 (en) Anti-emetic serotonin depleting agents
ATE59647T1 (de) Isoxazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutischen praeparate.
TR200000154T2 (tr) 2,4,4-Trisübstitüe-1,3-Dioksolan mantar önleyiciler.
MX9303392A (es) Derivados de imidazo benzoxazin-1-ona substituidos y proceso para su preparacion.
ES2073871T3 (es) Tiazolidin-2,4-dionas en el tratamiento de la hipertension.
IL111404A (en) Pharmaceutical compositions for the enhancement ofmemory and cognition comprising 3-aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles and some such novel compounds